|View printer-friendly version|
|Cynosure Reports 53% Increase in Revenues and Returns to Profitability in the Fourth Quarter of 2011|
Fourth-Quarter Financial Results
Revenues increased 53% to
"Strong organic growth in
Gross profit margin for the three months ended
"The improvement of our gross profit margin in the fourth quarter is particularly notable given the addition of ConBio's revenue," Davin said. "Historically, a significant share of ConBio's revenue has come from lower-margin international distribution. As a result, we anticipated that the acquisition would reduce our overall margin in the fourth quarter. Instead, our gross profit margin increased on a higher mix of direct North American ConBio sales, as well as the overall improvement in the U.S. business climate."
Total operating expenses for the fourth quarter of 2011 were
Recent Highlights: Cellulaze Receives FDA Clearance
Cynosure announced on
"With the addition of Cellulaze to our U.S. product lineup, Cynosure gains a critical first-mover advantage with the world's first aesthetic laser device for longer-lasting cellulite reduction," Davin said. "The product is supported by nearly four years of clinical research that we believe establishes Cellulaze as a new standard of care for this indication."
"We capped a year of steady top-line growth by posting our strongest quarter of 2011, and generating our first profitable quarter in more than three years," Davin said. "Propelled by an improving credit environment, momentum from newly acquired products and organic growth, our full-year revenue of
"With Cellulaze now
Fourth-Quarter Financial Results Conference Call
In conjunction with its fourth-quarter 2011 financial results, Cynosure will host a conference call for investors and analysts at
Any statements in this press release about future expectations, plans and prospects for